（商品説明）

自己免疫疾患、抗炎症で発生する炎症やアレルギー、免疫機能

をコントロールする薬です。

呼吸器、肺の病気、皮膚病、腸の病気、脊髄、脳や血液の病気、

また副腎の不調、アジソン病、癌に関するサプリメント、バクテリア

ショックなど幅広く免疫機能、自己免疫症に対して使われます。

この薬は動物や症状によって効果が異なり、また副作用を起こす場

合もございますので、ご使用に関しましては獣医師に相談されること

をお勧め致します。

製造国：イギリス

（使用方法）

－参考－

炎症を抑える目的でご使用の場合：0.2~0.6mg/kgを目安に１日２回まで服用。

免疫抑制を目的でご使用の場合：2~6mg/kgを目安に１日３回まで使用。

上記以外を目的でご使用の場合：0.2~6mg/kgを目安に適宜使用。

（使用期限）

ご注文時より最低１年以上有効

--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Prednicare 1mg 100tablets

Presentation White tablets each containing 1mg or 5mg Prednisolone Ph.Eur. Uses As an anti-inflammatory and anti-allergic agent for use in cats and dogs. Dosage and administration Single dose treatment may be appropriate for some specific conditions (anaphylaxis, etc.), but for more general treatment they may be given for one to three weeks at doses between: DOGS: 0.1–2.0mg/kg/day CATS: 0.1–2.0mg/kg/day The lowest effective dose must be used. Treatment should not be withdrawn suddenly. Problems of adrenal insufficiency should be minimised by dosing on alternate days, dosing to coincide with the endogenous cortisol peak (i.e. in the morning with regard to dogs and in the evening with regard to cats) and a gradual reduction of dosage. For the treatment of cats and dogs with tumours responsive to corticosteroid therapy the balance between the risks of therapy and the benefits of treatment may justify large doses. In such cases doses between 20mg/m2 every other day and 60mg/m2/day have been found to be useful. (Dose is related to the animal's estimated body surface area, in square metres.) Contra-indications, warnings, etc Systemic corticosteroid therapy is generally contra-indicated in patients with renal disease and diabetes mellitus. Administration is contra-indicated where corneal ulceration is present. It may render concurrent vaccination inoperative. Anti-inflammatory corticosteroids, such as prednisolone, are known to exert a wide range of side-effects. Whilst single high doses are generally well tolerated, they may induce severe side-effects in long term use and when esters possessing a long duration of action are administered. Dosage in medium to long term use should therefore generally be kept to the minimum necessary to control symptoms. Steroids themselves, during treatment, may cause Cushingoid symptoms involving significant alteration of fat, carbohydrate, protein and mineral metabolism, e.g. redistribution of body fat, muscle weakness and osteoporosis may result. During therapy effective doses suppress the Hypothalamo-Pituitreal-Adrenal axis. Following cessation of treatment, symptoms of adrenal insufficiency extending to adrenocorticol atrophy can arise and this may render the animal unable to deal adequately with stressful situations. Consideration should therefore be given to means of minimising problems of adrenal insufficiency following the withdrawal of treatment, e.g. dosing on alternate days, dosing to coincide with the time of the endogenous cortisol peak (i.e in the morning with regard to dogs and in the evening with regard to cats) and a gradual reduction of dosage (for further discussion see standard texts.) Systemically acting corticosteroids may cause polyuria, polydipsia and polyphagia, particularly during the early stages of therapy. Some corticosteroid's cause sodium and water retention and hypokalaemia in long term use. Some corticosteroids have caused deposition of calcium in the skin (calcinosis cutis). Corticosteroids are not recommended for use in pregnant animals. Administration in early pregnancy is known to have caused foetal abnormalities in laboratory animals. Administration in late pregnancy may cause early parturition or abortion. Corticosteroids may delay wound healing and the immunosuppressant actions may weaken resistance to or exacerbate existing infections. In the presence of bacterial infection, anti-bacterial drug therapy is usually required when steroids are used. In the presence of a viral infection, steroids may worsen or hasten the progress of the disease. Gastrointestinal ulceration has been reported in animals treated with corticosteroids and g.i.t. ulceration may be exacerbated by steroids in patients given non-steroidal anti-inflammatory drugs and in corticosteroid treated animals with spinal cord trauma. Steroids may cause enlargement of the liver (hepatomegaly) with increased serum hepatic enzymes. For animal treatment only. Not for use in animals intended for human consumption. Keep out of reach of children. Pharmaceutical precautions Store in a tightly closed original container, protected from light. Do not store above 25°C. Store in a dry place and protect from light. Legal category POM-V (previously POM) Packaging Quantities Containers of 500 or 1000 tablets. Further information Disposal: Any unused product or waste material should be disposed of in accordance with national requirements.